SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey(University of Rochester), William C. Gruber(Pfizer (United States)), Xuping Xie(The University of Texas Medical Branch at Galveston), Nicholas Kitchin(Johns Hopkins University), Kenneth Koury(Johns Hopkins University), Xia Xu(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), Kristin Tompkins(University of Rochester), Robert W. Frenck(Naval Medical Research Command), Stephen Lockhart(Johns Hopkins University), Philip R. Dormitzer(Boston Children's Hospital), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Alejandra Gurtman(Johns Hopkins University), Warren V. Kalina(Pfizer (United States)), Eleni Lagkadinou(BioNTech (Germany)), Uğur Şahin(Johannes Gutenberg University Mainz), Hongjie Xia(The University of Texas Medical Branch at Galveston), Edward E. Walsh(University of Rochester), Judith Absalon(GlaxoSmithKline (United States)), Kathrin U. Jansen(Pfizer (United States)), David Cooper(Johns Hopkins University), Özlem Türeci(Johannes Gutenberg University Mainz), Ruth Bailey(Johns Hopkins University), Jing Zou(Sichuan Cancer Hospital)
Cited by 420
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
|New England Journal of Medicine|2005|2.2k